The Global Health Body Issues Warning Over Critical Scarcity of Obesity Medications

Under a tenth of people who could benefit from weight-loss injections including Wegovy are able to get them, caution the WHO as it releases its first recommendations on the drugs.

Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging broader and more equitable availability to GLP-1 medication.

Based on forecasts, more than two billion will be obese by 2030 unless action is taken.

"Our new guidance recognises that excess weight is a chronic disease that can be managed with holistic and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and logistical bottlenecks are major barriers to broad access to the injections that can assist patients in reducing considerable weight, explains the organization.

Weight-Loss Drug Supply Crisis

Even under the current most favorable case, the supply of these medications would only suffice for around 100 million people – under 10% of the global need, according to the WHO.

The advice encourages nations and manufacturers to increase availability, by approaches including patent sharing.

The intellectual property rights on a key compound – the core component of a leading brand – is due to expire in several countries in 2026.

How Weight-Loss Drugs Operate

These medications replicate a biological compound to slow digestion, curb appetite and increase the sense of being full so people consume fewer calories.

Individuals commonly begin shedding pounds within a few weeks of starting on the once-weekly jabs.

Evidence indicates people may put most of the weight back on a year later of discontinuing the drug, as their typical food cravings return.

Being above a healthy weight elevates your chance for contracting medical conditions, like type 2 diabetes, heart disease, brain attack, and some malignancies.

Obesity affects individuals in all nations and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.